Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

The accuracy of immunoassay using a latex reagent is improved in a high CRP concentration range. Provided are C-reactive proteins generated by genetic recombination, 55% or more of the C-reactive proteins having a pyroglutamylated N-terminal.

A prostaglandin production method according to the present invention comprises reacting an unsaturated fatty acid with cyclooxygenase in the presence of a reducing agent. According to the present invention, it is possible to produce prostaglandins at a high yield.

The disclosure discloses an in-vivo continuous directed evolution system and application thereof, and belongs to the fields of gene engineering and enzyme engineering. The system includes Escherichia coli host bacteria carrying a random mutation module mutagenesis plasmid, a programmed death module toxin-antitoxin system and a target gene expression module target plasmid. The modules are coupled with one another, and target genes are subjected to multiple rounds of continuous mutation by virtue of the random mutation module mutagenesis plasmid in the system, so that the mutation rate of the target genes is further increased, and ultimately, efficient evolution and screening of the target genes in the host bacteria are realized. According to the system, mutations are accurately positioned on the target genes, random mutations in non-target gene regions are reduced, and the system has good practical value and can be applied to directed evolution of various different functional proteins.

There is provided an isolated E. coli strain deposited at the International Depositary Authority of Canada (IDAC) on Jun. 20, 2013 and attributed accession number 200613-01. There is also provided methods of using this strain for preventing edema disease or diarrhea caused by an F18 pathogenic E. coli infection in an animal.

This disclosure provides an E. coli strain, which lacks thioredoxin reductase activity encoded by trxB and thioredoxin 1 activity encoded by trxA, and glutathione reductase activity encoded by gor. Said E. coli strain expresses a mutated AhpC protein having glutathione reductase activity and a cytosolic prokaryotic disulfide isomerase. The E. coli strain has an oxidative cytosol and can be used to efficiently produce proteins having disulfide bonds.

The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.

Provided are a method of manufacturing a functional polysaccharide, the method including: preparing a cell containing a polysaccharide; crushing the cell to extract polysaccharide to the outside of the cell to obtain an extract; and purifying the extract by removing at least one of crude protein, crude fat, and crude powder from the extract, and a cosmetic composition for skin moisturizing or skin elasticity improvement, the cosmetic composition including the functional polysaccharide as an active ingredient.

An improved strain of E. coli for autoinduction of protein expression but also of autolytic enzymes thereby enabling combined autolysis and auto DNA/RNA hydrolysis. This combination of these two mechanisms improves cellular lysis and DNA removal and expounds the benefits of two stage production of a protein product. This system enables greater than 95% lysis and hydrolysis due to tightly controlled expression the genes. The autolytic genes may encode a lysozyme and a benzonase.

A living engineered glue system for performing autonomous mechanical repairs comprises a biofilm of microbial cells embedded in an extracellular matrix and operably linked in an environmentally-inducible, cell-cell communication genetic circuit to control gene expression.